Cash, cash equivalents and marketable securities: Cash, cash equivalents and marketable securities as of March 31, 2025 were $124.2 million, as compared to $152.8 million as of December 31, 2024. The Company believes that its cash, cash equivalents, and marketable securities are sufficient to fund its current operational plans through 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
- RPTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Repare Therapeutics Out-Licenses Platforms to DCx Biotherapeutics
- Cathie Wood Snags Robinhood Stock (HOOD) and GitLab (GTLB) as Markets Slide
- Repare Therapeutics Announces Leadership Changes in 2025
- Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds